JP2016518448A5 - - Google Patents

Download PDF

Info

Publication number
JP2016518448A5
JP2016518448A5 JP2016514017A JP2016514017A JP2016518448A5 JP 2016518448 A5 JP2016518448 A5 JP 2016518448A5 JP 2016514017 A JP2016514017 A JP 2016514017A JP 2016514017 A JP2016514017 A JP 2016514017A JP 2016518448 A5 JP2016518448 A5 JP 2016518448A5
Authority
JP
Japan
Prior art keywords
substituted
membered saturated
alkyl
compound
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016514017A
Other languages
English (en)
Japanese (ja)
Other versions
JP6376707B2 (ja
JP2016518448A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/037767 external-priority patent/WO2014186313A1/en
Publication of JP2016518448A publication Critical patent/JP2016518448A/ja
Publication of JP2016518448A5 publication Critical patent/JP2016518448A5/ja
Application granted granted Critical
Publication of JP6376707B2 publication Critical patent/JP6376707B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016514017A 2013-05-13 2014-05-13 サーチュイン調節剤としての置換架橋尿素類似体 Expired - Fee Related JP6376707B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361822758P 2013-05-13 2013-05-13
US61/822,758 2013-05-13
PCT/US2014/037767 WO2014186313A1 (en) 2013-05-13 2014-05-13 Substituted bridged urea analogs as sirtuin modulators

Publications (3)

Publication Number Publication Date
JP2016518448A JP2016518448A (ja) 2016-06-23
JP2016518448A5 true JP2016518448A5 (enExample) 2017-06-29
JP6376707B2 JP6376707B2 (ja) 2018-08-22

Family

ID=53264426

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016514017A Expired - Fee Related JP6376707B2 (ja) 2013-05-13 2014-05-13 サーチュイン調節剤としての置換架橋尿素類似体
JP2017526877A Expired - Fee Related JP6833686B2 (ja) 2013-05-13 2015-11-19 サーチュイン調節剤としての置換架橋尿素類似体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017526877A Expired - Fee Related JP6833686B2 (ja) 2013-05-13 2015-11-19 サーチュイン調節剤としての置換架橋尿素類似体

Country Status (11)

Country Link
US (4) US9765075B2 (enExample)
EP (2) EP2997029B1 (enExample)
JP (2) JP6376707B2 (enExample)
KR (2) KR20160006215A (enExample)
CN (2) CN105392788B (enExample)
AU (3) AU2014265671B2 (enExample)
BR (2) BR112015028613A2 (enExample)
CA (2) CA2912683A1 (enExample)
ES (1) ES2718550T3 (enExample)
RU (2) RU2015153061A (enExample)
WO (1) WO2014186313A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2982670B1 (en) * 2013-04-04 2018-11-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
RU2015153061A (ru) 2013-05-13 2017-06-15 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Замещенные связанные мостиковой связью мочевинные аналоги в качестве модуляторов сиртуина
JP2016079173A (ja) * 2014-10-15 2016-05-16 日本合成化学工業株式会社 新規ピリジン系化合物、それを用いたアニオン硬化性化合物用硬化剤、硬化性組成物及び硬化物
CN107207521A (zh) 2014-11-19 2017-09-26 葛兰素史密斯克莱知识产权(第2 号)有限公司 作为沉默调节蛋白调节剂的取代的桥连脲类似物
WO2016095089A1 (en) 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
WO2016095088A1 (en) * 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
US10364245B2 (en) 2017-06-07 2019-07-30 Chiesi Farmaceutici S.P.A. Kinase inhibitors
CN111511723A (zh) * 2017-08-21 2020-08-07 米可如比奥提克斯有限公司 用作抗菌剂的代谢稳定的n-酰基氨基噁二唑
JP7156207B2 (ja) * 2019-08-07 2022-10-19 株式会社島津製作所 糖ペプチド解析装置
CN112759593A (zh) 2019-11-01 2021-05-07 北京伯汇生物技术有限公司 桥环并醛基吡啶衍生物及其应用
CN112094362B (zh) * 2020-09-29 2022-04-12 四川大学华西医院 烟酰胺核糖或单核苷酸类似物-大分子载体轭合物及制法和应用
CN112645805A (zh) * 2020-12-23 2021-04-13 北京理工大学 一种由温勒伯酰胺制备均苯三甲醛的方法
CN115518062B (zh) * 2022-09-02 2024-03-22 成都大学 Phellopterin在制备用于治疗STAT信号通路介导的相关疾病药物中的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE4424484A1 (de) 1994-07-12 1996-01-18 Bayer Ag Azofarbstoffe, deren Herstellung und Verwendung
CA2573673A1 (en) * 2004-07-16 2006-01-26 Proteosys Ag Muscarinic antagonists with parp and sir modulating activity as cytoprotective agents
EP1850840A2 (en) * 2005-01-13 2007-11-07 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
WO2006094248A1 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Aryl-substituted cyclic sirtuin modulators
WO2006094210A2 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Tetrahydroquinoxalinone sirtuin modulators
US20060229265A1 (en) 2005-03-30 2006-10-12 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
WO2008029096A2 (en) 2006-09-04 2008-03-13 University Court Of The University Of Dundee P53 activating benzoyl urea and benzoyl thiourea compounds
PE20091157A1 (es) * 2007-12-21 2009-09-03 Astrazeneca Ab Derivados biciclicos para usar en el tratamiento de afecciones asociadas con el receptor de androgeno - 155
CA2723135A1 (en) 2008-05-01 2009-11-05 Sirtris Pharmaceuticals, Inc. Quenolines and related analogs as sirtuin modulators
CA2738794C (en) 2008-09-29 2016-01-05 Sirtris Pharmaceuticals, Inc. Chromenone analogs as sirtuin modulators
BRPI0919625A2 (pt) * 2008-10-29 2015-12-01 Sirtris Pharmaceutical Inc piriridina, piridina bicíclica e análogos relacionados como moduladores de sirtuína
BRPI0922435A2 (pt) 2008-12-19 2018-09-11 Sirtris Pharmaceuticals Inc "composto de tiazolopiridina moduladores de sirtuina, composição farmacêutica compreendendo o mesmo e seu uso."
WO2011059839A1 (en) * 2009-10-29 2011-05-19 Sirtris Pharmaceuticals, Inc. Bicyclic pyridines and analogs as sirtuin modulators
BR112014009348A2 (pt) 2011-10-20 2017-04-18 Glaxosmithkline Llc aza-heterociclos substituídos bicíclicos e análogos como moduladores de sirtuina
WO2016081692A2 (en) 2014-11-19 2016-05-26 Glaxosmithkline Llc Substituted bridged urea analogs as sirtuin modulators
RU2015153061A (ru) 2013-05-13 2017-06-15 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Замещенные связанные мостиковой связью мочевинные аналоги в качестве модуляторов сиртуина

Similar Documents

Publication Publication Date Title
JP2016518448A5 (enExample)
MX375970B (es) Compuestos de triazolopirimidina y usos de los mismos.
MX392440B (es) Inhibidores de tirosina quinasa de bazo (syk).
MX383051B (es) Compuestos que inhiben eif4a y métodos relacionados a los mismos.
PE20181093A1 (es) Compuestos heterociclicos y usos de los mismos
MX383686B (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
MX2014015501A (es) Carboxamidas heterociclicas fungicidas.
AR096238A1 (es) Proceso para preparar derivados de 3-((2s,5s)-4-metilen-5-(3-oxopropil)tetrahidrofuran-2-il)propanol e intermediarios útiles para el mismo
JP2016526024A5 (enExample)
AR103222A1 (es) Procedimiento para la preparación de análogos de 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidina
MX377552B (es) Proceso para preparar un compuesto antiviral de formula i.
AR100442A1 (es) Derivados de pirido[1,2-a]pirimidin-4-ona para tratar atrofia muscular espinal
MX375261B (es) Compuestos aromaticos sustituidos para el tratamiento de la fibrosis pulmonar, la fibrosis hepatica, la fibrosis de la piel y la fibrosis cardiaca.
CU20150014A7 (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
BR112016007427A2 (pt) compostos de pirazol-amida e usos dos mesmos
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
MX2015003594A (es) Agente terapeutico o profilactico para sindrome de lisis tumoral.
RU2020123900A (ru) Новые соединения, ингибирующие mtor
CU20150084A7 (es) Derivados del ácido 4-((1,1) bisfenil -4-il)-3-(3-fosfonopropanamido)butanoico,activo como inhibidores de nep(endopeptidasa neutral)
CA2920410C (en) Thienopiperidine derivative and use thereof
PE20181274A1 (es) Compuestos utiles para inhibir ror-gamma-t
PH12015502717B1 (en) Anti-fibrogenic compounds, methods and uses thereof
PE20131327A1 (es) Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparacion, y las composiciones farmaceuticas que la contienen
MX388141B (es) EL USO DE DERIVADOS DE ÁCIDOS GRASOS POLINSATURADOS PARA REDUCIR apoC-III.